Stryker's Commentary on M&A

"We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's and if you look at S&P, we went from an A plus to A rating. We're committed to maintaining investment grade, but there's obviously a large gap between A rating and the low end of investment grade. Keep in mind that the vast majority of the deals we do are small tuck-in deals. That will continue to be the case for Stryker. That is where we drive the most value and we find great technologies that we can give to our fabulous sales forces to drive.

...

May 13th, 2016
0

Smith & Nephew's Commentary on M&A

"Our entry into the fast-growing area of orthopedic robotic-assisted surgery with the acquisition of Blue Belt is off to a good start. The integration has been smooth. And we’re excited about the prospects and our pipeline . . .

So the mid-tier was really one of a number of interests that we have in M&A. As you know M&A remains one of our five key strategic pillars. There’s no change really in the level of interest. Clearly, there are a number of areas that we’re focused on in terms of high growth areas in...

May 13th, 2016
0

Hologic's Commentary on M&A

"Yes we are ready and willing to spend there on M&A and actually we did make an acquisition of our own stock in the quarter. That was actually a pretty good acquisition that we made and we are feeling pretty good about that.

The teams are definitely looking and where Bob and Eric and I are now reviewing on a more regular basis ideas . . . Ultimately I look forward to the day that we have no converts left on the balance sheet, but I would suspect we will be doing some acquisitions along the way while we continue to clean those up....

May 13th, 2016
0

Boston Scientific's Commentary on M&A

"Near term, our capital allocation priorities are to prepay debt, manage our contingencies, and pursue tuck-in M&A."

Daniel Brennan, Boston Scientific CFO, according to a Seeking Alpha transcript of the company's first quarter earnings call

...
May 13th, 2016
0

BD's Commentary on M&A

"As many of you already know, in March, we celebrated the one-year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration and a significant amount of work driven by the integration teams across the businesses . . .

In the short run, we still have the flexibility to do plug-in acquisitions."

Vincent Forlenza, BD chairman, president, and CEO...

May 13th, 2016
0

Baxter's Commentary on M&A

"We talk about M&A, and obviously M&A is opportunistic, but transformative M&A is not in the cards as we speak right now. So we're looking at strengthening our current core businesses, and by doing it, we're going to go into adjacencies . . .

As currency weakens in some countries in Latin America, offers an opportunity for potential acquisitions there at a reasonable price, with a good return on investment. . . 

We also will be very...

May 13th, 2016
0

2016 has already been a busy year for mergers and acquisitions. Will the robust M&A activity in the medtech industry continue?

M&A in recent years has dramatically transformed the medtech industry, and executives have continued to sign deals, with several transactions worth hundreds of millions and the Abbott-St. Jude Medical megamerger already announced this year.

Will medtech keep up this brisk purchasing pace? Do fewer potential targets mean fewer future deals? With large medical device companies snapping up other companies, will the need for integration and time to digest those acquisitions delay or prevent other transactions?

Read on for more recent commentary from...

May 13th, 2016
0

A design expert identifies the major consumer trends that are influencing medical device design and how device makers can embrace patient-centric design.

Marie Thibault

Yuhgo Yamaguchi, principal design strategist at Continuum, thinks deeply about how patients and caregivers use a health product and how design choices can improve those devices.

MD+DI spoke with Yamaguchi to learn more about the process he uses to design a human-centered medical device. Read on to find out why he...

May 13th, 2016
0

The numbers tell the story behind what is leading large medtech to develop implantable devices that can work even when patients undergo MRI scans.

Arundhati Parmar

Big medtech companies are all developing devices whose functionality is not hampered when patients undergo magnetic resonance imaging (MRI), a common diagnostic tools these days.

In early May, Medtronic announced the FDA clearance of its MR-Conditional StrataMR valves and shunts that are part of the company's Strata line of Adjustable Valve Systems used in the treatment of patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. In February it announced the availability of an MR-...

May 11th, 2016
0

Medtech companies that set up shop in Israel enjoy a host of benefits, such as government support, but they also face challenges as they seek to extend their global reach.

Barry Levenfeld and Daniel Green

Israel’s medical device industry continues to astonish. Recent successes attracting global attention include the following:

  • Given Imaging. Given Imaging developed the PillCam, an ingestible imaging capsule facilitating the visualization and detection of gastrointestinal disorders. Founded in 1988, it received CE approval and went public on the NASDAQ in 2001. In 2014, Covidien (now Medtronic) acquired Given Imaging for $860 million.
  • ...
May 11th, 2016
0